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Abstract
Background: Whether testosterone treatment has benefits on body composition over and above caloric restriction
in men is unknown. We hypothesised that testosterone treatment augments diet-induced loss of fat mass and
prevents loss of muscle mass.
Methods: We conducted a randomised double-blind, parallel, placebo controlled trial at a tertiary referral centre. A
total of 100 obese men (body mass index ≥ 30 kg/m2) with a total testosterone level of or below 12 nmol/L and a
median age of 53 years (interquartile range 47–60) receiving 10 weeks of a very low energy diet (VLED) followed by
46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of 10-weekly intramuscular
testosterone undecanoate (n = 49, cases) or matching placebo (n = 51, controls). The main outcome measures were
the between-group difference in fat and lean mass by dual-energy X-ray absorptiometry, and visceral fat area
(computed tomography).
Results: A total of 82 men completed the study. At study end, compared to controls, cases had greater reductions
in fat mass, with a mean adjusted between-group difference (MAD) of –2.9 kg (–5.7 to –0.2; P = 0.04), and in visceral
fat (MAD –2678 mm2; –5180 to –176; P = 0.04). Although both groups lost the same lean mass following VLED
(cases –3.9 kg (–5.3 to –2.6); controls –4.8 kg (–6.2 to –3.5), P = 0.36), cases regained lean mass (3.3 kg (1.9 to 4.7),
P < 0.001) during weight maintenance, in contrast to controls (0.8 kg (–0.7 to 2.3), P = 0.29) so that, at study end,
cases had an attenuated reduction in lean mass compared to controls (MAD 3.4 kg (1.3 to 5.5), P = 0.002).
Conclusions: While dieting men receiving placebo lost both fat and lean mass, the weight loss with testosterone
treatment was almost exclusively due to loss of body fat.
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Background
The obesity epidemic is associated with adverse health
outcomes and high socioeconomic costs. Modest weight
loss provides important health benefits, but successful
weight loss is difficult to achieve and maintain. Although
most studies testing interventions for obesity focus on
body weight, excess body fat is considered responsible
for most obesity-associated health risks and associated
with increased mortality independent of body mass index
(BMI) [1]. Adiposity contributes to loss of muscle mass
and function, with sarcopenia increasing insulin resist-
ance, a self-perpetuating phenotype termed “sarcopenic
obesity” [2]. Therefore, the benefit of energy restriction
may be limited by loss of lean body mass [2].
In men, obesity is the single most important factor
associated with low testosterone, overriding the effects
of age and comorbidities [3]. Obese men have 30 %
lower total testosterone (TT) levels compared to lean
men [3], and 40 % have levels lower than 12 nmol/L
[3], the lower limit reported for healthy young men
[4]. This reduction in total testosterone levels is in
part due to the obesity-associated lowering in sex
hormone binding globulin (SHBG). However, espe-
cially with more marked obesity, free testosterone
levels are also reduced due to adiposity-associated
suppression of the gonadal axis at the hypothalamic
level. While the exact mechanisms are not fully
understood, experimental studies in humans suggest
that fat-derived adipokines and pro-inflammatory me-
diators may play a role in this central gonadal axis
suppression [5]. In addition, preclinical evidence has
shown that testosterone deficiency promotes adipose
tissue accumulation but reduces myogenesis via an
androgen receptor mediated pathway [6]. This bidir-
ectional relationship between lowered testosterone
and obesity is supported by clinical studies – weight loss
increases testosterone proportionally to weight loss [7]
and testosterone treatment reduces body fat [8].
Whether testosterone treatment augments fat loss
additive to caloric restriction or prevents diet-associated
loss of muscle mass is unknown. We conducted a rando-
mised clinical trial in obese men with low to low-normal
total testosterone to test the hypothesis that, following
diet-induced loss of fat mass, testosterone treatment will
prevent fat regain but maintain lean mass.
Methods
Study design
This 56-week, randomised, double-blind, placebo con-
trolled trial (RCT) (ClinicalTrials.gov NCT01616732)
was conducted at a tertiary referral centre (Austin
Health, Melbourne, Australia). The study was approved
by the Human Research Ethics Committee, Austin
Health (HREC 2012/04495).
Participants
Adult men aged 18–70 years recruited from the local
community via print, radio and television advertise-
ments were eligible to participate if they were obese
(BMI ≥ 30 kg/m2) and had two TT levels of or below
12 nmol/L measured in the morning in the fasting
state at least one week apart. Exclusion criteria were
pathological androgen deficiency due to pituitary or
testicular disease, testosterone treatment during the
previous 12 months, prostate disease, cancer, haem-
atocrit above 50 %, symptomatic ischaemic heart dis-
ease, cardiovascular event in preceding 12 months,
congestive cardiac failure above NYHA Class I, blood
pressure above 160/100 mm Hg despite antihypertensives,
uncontrolled obstructive sleep apnoea, chronic kidney dis-
ease (estimated glomerular filtration rate < 40 mL/min),
use of weight-altering medications including insulin and
glucagon-like peptide 1-agonists, previous very low energy
diet (VLED) failure, bariatric surgery, major depression,
recreational drug use, and alcohol dependence. Each par-
ticipant provided written informed consent prior to inclu-
sion in the study.
Randomisation and masking
Subjects were randomly assigned in a concealed 1:1 allo-
cation to either testosterone or placebo using a block of
size four with equal probability to the two treatments
within four strata accounting for BMI (≤ or > 37 kg/m2)
and age (≤ or > 60 years). The randomization sequence
was generated by an independent statistician and imple-
mented by the Austin Health clinical trials pharmacists.
Participants, trial investigators and pharmacists were
blinded to treatment allocation.
Procedures
Men received either 1000 mg testosterone undecanoate
(the standard ampoule strength in Australia) or visu-
ally identical placebo in oily base by deep intramuscu-
lar buttock injection at weeks 0 and 6 (manufacturer-
recommended loading dose), and 10-weekly thereafter
at weeks 16, 26, 36 and 46. The 10-weekly interval, in line
with the manufacturer’s recommendations (10–14 weeks),
was chosen to ensure therapeutic trough levels of 10–
15 nmol/L [9] in obese men. Trough levels represent the
therapeutic target immediately prior to the next dose and
are lower than steady state targets (e.g. 13.9–24.3 nmol/L)
recommended for topical treatment [10].
During weeks 1 to 8 subjects were instructed to re-
place all of their three principal daily meals with a VLED
formulation (Optifast® VLED, Nestle, Australia) provid-
ing 640 kcal per day and two cups of low-starch vegeta-
bles. During weeks 9–10, subjects weaned their VLED
and ordinary foods were gradually reintroduced. After
10 weeks, subjects had completely ceased the VLED
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and were instructed to follow an energy-restricted
diet based on the Australian Commonwealth Scientific
and Industrial Research Organisation Total Wellbeing
diet (1350 kcal/d) for the remaining 46 study weeks aimed
at preventing weight regain [11]. Subjects underwent
weighing and individual counselling at every visit and were
provided with written information to ensure dietary
compliance. Subjects were advised to perform at least
30 minutes of moderate-intensity exercise each day and
completed exercise questionnaires and accelerometer test-
ing (at weeks 0, 10 and 56), with feedback given, to
reinforce and encourage participation in exercise.
Schedule of assessment and measurements
Subjects underwent long assessments at weeks 0, 10 and
56, including clinical assessment, physical function tests,
accelerometer fitting (worn 7 days), questionnaires,
fasting morning blood tests, dual-energy X-ray absorpti-
ometry (DXA) scan for body composition and abdom-
inal computed tomography (CT) scans for visceral fat,
and short assessments (weeks 2, 4, 6, 16, 26, 36 and 46)
for clinical assessment and to ensure dietary compliance.
Adherence to the diet was estimated by measuring body
weight at each study visit, with individualised feedback
given.
Sex steroid measurements
All blood samples were drawn in the morning (8–10 am),
in the fasted state. Because liquid chromatography-
tandem mass spectroscopy (LCMS/MS) was not available
for routine clinical use, TT was initially measured by
electrochemiluminescence immunoassay used at the
study hospital for routine clinical care (Roche Cobas
C8000, Roche Diagnostics, Rotkreuz, Switzerland).
The Austin Health intra-assay coefficient of variability
(CV) was 6.9 % at 4.3 nmol/L and 5 % at 37.5 nmol/L. To
confirm lowered levels, baseline TT was re-measured
at study completion by validated LCMS/MS [12] from
frozen baseline samples stored at –80 °C. SHBG was
measured by electrochemiluminescence immunoassay
(Roche Cobas C8000), Austin intra-assay CV of 3.4 %
at 44 nmol/L. Free testosterone was calculated ac-
cording to Vermeulen [13].
Metabolic parameters (fasting lipid profile, HbA1c,
fasting glucose and c-peptide levels) and safety parame-
ters (haemoglobin, haematocrit and prostate-specific
antigen (PSA)) were measured at the study hospital with
assay technology used for routine clinical care as de-
scribed [14].
An independent investigator reviewed week 26 safety
parameters for pre-defined withdrawal criteria: haemo-
globin > 180 g/L, haematocrit > 0.54 or PSA > 5.5 μg/L.
Body composition including appendicular lean mass
(ALM) corrected for height squared (ALM/height2) was
measured by DXA (DXA Prodigy, Version 13.60; GE
Lunar, Madison, WI, USA). Visceral fat was quantified
from single axial CT images at the L4-5 intervertebral
disc space using SliceOmatic (version 4.2; Tomovision,
Montreal, Canada) by a blinded investigator (MR) with
an intra-observer CV of 0.56 %. Step counts, physical
and sedentary activity over 7 consecutive days were
measured using the GT3x accelerometer (ActiGraph,
Pensacola, FL, USA). Physical performance was assessed
at weeks 0, 10 and 56 by four tests performed in du-
plicate and scored as the sum of the fastest times for
each test in seconds: a 15 m rapid walking test, a
3 m up-and-go test, stair climbing and stair descend-
ing with a weighted vest. Handgrip was measured in
the dominant hand using a hand-held medical dyna-
mometer (Jamar 5030J1, Sammons Preston, Bolingbrook,
IL, USA).
Outcomes
The primary outcome measure was the difference in fat
mass between testosterone- and placebo-treated men at
study end (56 weeks) by DXA. Other main outcome
measures included change in lean mass (DXA), visceral
abdominal tissue (CT) and body weight. Further out-
come measures included anthropometric measurements,
handgrip, physical function, physical activity and meta-
bolic parameters.
Statistical analysis
The power analysis for this study was based on the effect
of testosterone undecanoate on fat mass reduction of
5.6 kg reported in a previous RCT [15]. Given that pre-
vious studies have shown that dieting leads to loss of fat
mass, we expected that the placebo group would retain
some degree of fat loss by the end of the study. We
therefore proposed a fat mass difference of 10 % and
common standard deviation of 15.49, requiring a total of
49 subjects to achieve 90 % power for a two-sample t-
test comparing mean percentage fat mass loss between
the two groups. To account for a 50 % attrition rate, 100
subjects were required.
Repeated measures of main outcome continuous data
were analysed using linear mixed models (LMEs) with
random intercepts to account for within-individual cor-
relation over time. LME random effect and residual nor-
mality assumptions were checked and resulted in no
noteworthy violations. Restricted maximum likelihood
estimates were used and the LME model covariates in-
cluded factor variables ‘weeks’ and ‘treatment’ and were
further adjusted for baseline testosterone and age. An
intention-to-treat analysis was also carried out where the
outcome measures for study dropouts were returned to
baseline. Together with the LME analysis of the raw data,
the LME return-to-baseline analysis provides protection
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against biases introduced due to missing data. Data shown
are mean and 95 % confidence interval (CI). The mean
adjusted difference (MAD) plus 95 % CI refers to the dif-
ference between groups of mean change in the main out-
come measures over time.
Separate models with similar characteristics were used
to assess other outcome data and safety variables. To
compare repeated measurements of variables within
groups between two time points, the t-test was used.
Data shown are mean and 95 % CI. All tests were two-
tailed with P < 0.05 denoting statistical significance. No
adjustments were made for multiple comparisons on
other variables. Comparison of baseline characteristics
was based on the t-test or χ2 test in case of categorical
variables. In the case of low numbers, the Fisher exact
test was used. Data shown are mean (standard deviation)
or median (interquartile range), based on normality test-
ing, using the Kolmogorov-Smirnov test with Lilliefors
correction. All analyses of means were complemented
with Wilcoxon non-parametric tests. Similar results
were found so the results were not reported. Analyses
were conducted using R version 3.01 and SPSS version
22 (SPSS Inc., Chicago, IL).
The wider variation and influence of few strong re-
sponders observed in the main outcome of fat mass, typ-
ical for obesity trials, was addressed in a sensitivity
analysis using a robust mixed linear model, as imple-
mented by the r package robustlmm [16]. This model
corrects for natural heteroskedasticity and the potential
influence of exceptional responders by introducing a
weighing algorithm and Design Adaptive Scale estimate
according to Koller [16], which is less sensitive to out-
liers in data than the squared error loss.
Results
Study subjects
Between April 2013 and October 2014, we assessed 584
men for eligibility. Of these, 264 men proceeded to
screening investigations and 164 were ineligible, chiefly
due to a TT level above 12 nmol/L (n = 158) (Fig. 1).
The remaining 100 men were randomised to testoster-
one (n = 49, cases) or placebo (n = 51, controls); 82 men
completed the trial, of which 44/49 (90 %) were cases
and 38/51 (75 %) controls (P = 0.099). The most com-
mon reason for non-completion was failure to attend
visits (cases = 3, controls = 12).
Baseline characteristics were comparable between the
groups (Table 1). By study end, trough TT increased to
14.1 nmol/L (recommended trough range 10–15 nmol/L)
in cases and 10.0 nmol/L in controls, both P < 0.05
compared to baseline and significantly different be-
tween groups (P < 0.001), with similar changes in cal-
culated free testosterone. Luteinising hormone levels
decreased from 4.5–0.4 IU/L in cases, but remained
unchanged in controls (4.2–4.2 IU/L; P < 0.001 between
groups) (Additional file 1: Figure S1).
Change in main outcome measures
At the end of the 10-week VLED phase, both cases
(–12.0 kg; –14.5 to –9.5) and controls (–13.5 kg; –16.0 to
–11.0) lost the same body weight, with no difference in
body composition (Table 2).
Following resumption of normal foods as part of an
energy restricted diet shown to prevent weight regain,
from week 10 onwards for a further 46 weeks, body
weights remained largely stable from week 10 until
study end (week 56) (Additional file 1: Figure S2). In
particular, men receiving testosterone maintained
weight loss (P = 0.62), while there was weight regain
in the placebo group (P = 0.06). At study end, cases
had, compared to baseline, lost significantly more fat
mass (MAD –2.9 kg (–5.7 to –0.2), P = 0.04), fat mass
percentage (MAD –2.8 % (–4.6 to –1.0), P = 0.003)
and visceral fat (MAD –2678 mm2 (–5180 to –176),
P = 0.04), whilst regaining diet-induced loss of lean
mass (MAD 3.4 kg (1.3–5.5), P = 0.002) (Table 2).
During weeks 10–56, loss of fat mass percentage was
greater in cases than in controls (MAD –2.1 % (–3.9
to –0.2), P = 0.03).
As the combined lean and fat mass lost in controls
was similar to the amount of fat mass lost in the cases,
the difference in body weight change at study end was
no different between groups (MAD –0.5 kg (–4.3 to 3.3),
P = 0.80) (Table 2). Age, baseline TT, luteinising hor-
mone and SHBG levels were all not predictive of
changes in body composition after 56 weeks in the trial.
Further, baseline fat mass did not interact with the
changes in body composition. In addition, adjustment
for physical activity did not alter the findings.
Other outcomes
Compared to controls, cases retained higher ALM/
height2 (0.45, P < 0.001) (Table 3). Cases had a signifi-
cant increase in handgrip strength compared to pla-
cebo (3.6 kg, P = 0.03). Both groups increased their
daily step counts (P < 0.01) and activity levels (P < 0.05) at
10 weeks. At study end, daily step count was in-
creased significantly in cases by 931 steps (P = 0.03),
as was percentage of daily non-sedentary time (+1.5 %,
P = 0.03). This was due to spending less time in seden-
tary and more time in light activity (P = 0.016). No sig-
nificant changes in either outcome were observed in
controls nor between groups at study end (Table 3).
Both groups improved on physical performance testing
but there was no difference between groups at study
end. Similarly, both groups had improvements in meta-
bolic parameters without between-group differences
(Table 3).
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Sensitivity analyses
Outcomes were unchanged after imputation of missing
values using an intention-to-treat analysis and return-to-
baseline for missing data (Additional file 1: Table S1;
MAD for fat mass (–3.3 kg, P = 0.014), visceral abdom-
inal tissue (–3223 mm2, P = 0.007) and for lean mass
(2.3 kg, P = 0.015)). Similar findings were also found
using non-parametric tests.
In an additional sensitivity analysis, when re-analysed
with a robust linear mixed model (see Methods), the
main outcome fat loss after 56 weeks was more pro-
nounced in the testosterone group, compared to the pla-
cebo group (–4.1 kg (–5.6 to –2.7), P < 0.01).
Compared to participants completing the study (n = 81),
non-completers (n = 19) lost less body weight (–8.2 kg
(–12.1 to –6.2) vs. –13.4 (–17.2 to –9.9), P = 0.027), and less
fat mass (–5.2 kg (–7.2 to –3.7) vs. –8.1 (–10.7 to –4.9),
P = 0.009) at week 10, the end of the VLED phase. Similar
findings were also observed if non-completers in the pla-
cebo group were analysed separately (data not shown).
Fig. 1 Trial profile. Shown is study enrolment and follow-up. The most common reason for non-completion was failure to attend visits. Serious
adverse events are detailed in Table 4. BMI body mass index, CKD chronic kidney disease, CCF congestive cardiac failure, OSA obstructive sleep
apnoea, VLED very low energy diet
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Adverse events
There was no between-group difference in overall ad-
verse events, or serious adverse events which were few
(Table 4). One case had a rise in haemoglobin above the
predetermined safety limit of above 180 g/L occurring at
study end. Three men were withdrawn from the study
due to PSA rise (cases = 1) and major cardiovascular
events (cases = 1, controls = 1).
Discussion
The major novel findings of this RCT are that, among
obese men with low to low-normal testosterone submit-
ted to a weight loss program, testosterone treatment de-
creased total fat mass and visceral adipose tissue, and
protected against loss of total and appendicular lean
mass. At the end of the initial 10-week VLED phase,
while men lost substantial amounts of weight similar to
previous successful VLED studies [11], there were no
differences in weight loss or body composition changes
between the two groups. However, differences emerged
in the weight maintenance phase, during which men re-
ceiving testosterone maintained weight loss (P = 0.62),
while there was marginal weight regain in the placebo
group (P = 0.06). At study end, there were marked differ-
ences in body composition between groups, and men re-
ceiving testosterone had greater reductions of fat mass
(–2.9 kg) and visceral fat area (–2678 mm2) compared to
placebo. After the VLED phase, men receiving testoster-
one regained lean mass (3.3 kg, P < 0.001) in contrast to
placebo (0.8 kg, P = 0.29), so that at study end, lean mass
was 3.4 kg higher in testosterone-treated men. Overall,
our results indicate that, compared to men receiving pla-
cebo who lose both fat and muscle mass during diet, tes-
tosterone treatment shifts this weight loss to almost
exclusive fat mass loss.
Our trial has several strengths distinguishing it from
previous testosterone trials, most importantly, the suc-
cessful implementation of a rigorous weight loss pro-
gram and the exclusive focus on men with established
obesity. By contrast, previous RCTs examining the ef-
fects of testosterone on body composition recently
meta-analysed [8] were neither designed for weight loss
nor had obesity as a selection criterion. Moreover, only a
few studies, not all placebo controlled, have combined
testosterone treatment with lifestyle measures. A recent
meta-analysis of these studies [17] suggested that testos-
terone treatment may have added benefits on body com-
position, consistent with our findings. We confirmed
lowered baseline testosterone levels using LCMS/MS
technology [12], used intramuscular testosterone elimin-
ating compliance issues for a relatively long duration in
a double-blind placebo controlled design, and attrition
rate was relatively low. Compared to men completing
the study, non-completers had lost less body weight and







Age, years 54.3 (47.3–59.8) 52.8 (47.6–60.1) 0.93
Weight, kg 118.3 (15.7) 120.7 (19.6) 0.51
BMI, kg/m2 37.5 (34.9–40.5) 37.3 (34.7–41.6) 0.60
Waist circumference, cm 124 (118–131) 123 (117–136) 0.62
SBP, mmHg 135 (14) 130 (13) 0.06
DBP, mmHg 80 (78–88) 80 (78–85) 0.85
Handgrip, kg 44 (41–50) 46 (40–55) 0.65
Fat mass, kg 44.3 (10.0) 46.4 (10.6) 0.30
Fat mass, % 38.8 (33.5–42.3) 38.9 (36.0–43.5) 0.208
Lean mass, kg 68.1 (7.3) 67.4 (9.1) 0.67
ALM/height2, kg/m2 9.7 (1.0) 9.6 (0.8) 0.35
VAT area, mm2 25,088 (8617) 24,836 (9557) 0.89
Ischemic heart diseasea 6 (12.2 %) 6 (11.8 %) 0.94
Diabetes 10 (20.4 %) 12 (23.5 %) 0.71
Metformin 3 (6.1 %) 3 (5.9 %) 0.96
Statin use 14 (28.6 %) 15 (29.4 %) 1.0
Steps per day 6378 (4761–7543) 6371 (4816–7440) 0.79
Activity (%/day) 14.2 (5.7) 13.5 (4.5) 0.49
Physical performance test (sec) 36.2 (32.5–41.6) 37.1 (33.1–40.5) 0.40
TT, nmol/L, ECLIA 8.2 (2.5) 8.4 (2.3) 0.65
TT, nmol/L, LCMS/MS 6.8 (2.0) 7.0 (1.6) 0.55
cFT, pmol/L, ECLIA 195 (58) 208 (55) 0.23
cFT, pmol/L, LCMS/MS 159 (46) 172 (44) 0.15
SHBG, nmol/L 25 (18–31) 21 (17–26) 0.17
LH, IU/L 4.5 (3.3–5.6) 4.2 (3.1–5.2) 0.70
Fasting glucose, mmol/L 5.8 (5.3–6.1) 5.8 (5.4–6.4) 0.72
HOMA-IR 3.3 (1.0) 3.6 (1.1) 0.27
HbA1c, % 6.0 (5.6–6.2) 6.1 (5.8–6.5) 0.23
Total cholesterol, mmol/L 5.1 (4.3–5.6) 4.8 (4.4–5.7) 0.60
LDL-c, mmol/L 2.9 (0.9) 2.9 (1.0) 0.99
HDL-c, mmol/L 1.1 (1.0–1.3) 1.2 (1.0–1.3) 0.58
Triglycerides, mmol/L 1.9 (1.4–2.4) 1.7 (1.2–2.5) 0.38
Haematocrit 0.43 (0.02) 0.44 (0.02) 0.003
Haemoglobin, g/L 148 (8) 152 (9) 0.014
PSA, μg/L 0.7 (0.5–1.1) 0.7 (0.5–1.2) 0.79
Data are mean (SD), median (IQR) based on normality testing, using the
Kolmogorov–Smirnov test with Lilliefors correction, or number (%). P values
were calculated for the difference between groups using t-test, Wilcoxon
Signed Ranks Test, χ2 test, or Fisher exact test; P < 0.05 was considered significant
aIschaemic heart disease denotes previous acute myocardial infarction,
coronary artery bypass grafting, percutaneous transluminal coronary angioplasty
BMI body mass index, DBP diastolic blood pressure, SBP systolic blood
pressure, ALM appendicular lean mass, VAT visceral abdominal tissue, SHBG sex
hormone binding globulin, TT testosterone, cFT calculated free testosterone,
ECLIA electrochemiluminescence immunoassay, LCMS liquid chromatography-
tandem mass spectroscopy, LH luteinising hormone, HbA1c glycated
haemoglobin, LDL-c low density lipoprotein cholesterol, HDL-c high density
lipoprotein cholesterol, PSA Prostate-specific antigen
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less fat mass at the end of the VLED phase of the study.
Therefore, if anything, this would be expected to under-
estimate the benefits of testosterone treatment, espe-
cially as the drop-out rate was higher among men
assigned to placebo compared to testosterone treatment.
Although it may be expected that the effects of testos-
terone treatment are attenuated in the context of a
rigorous weight loss program, the reduction of fat mass
observed here compares favourably with the 1.6–2.0 kg
reduction reported in meta-analyses of RCTs not incorp-
orating weight loss measures [18, 19]. This may be be-
cause we focused on obese men with a confirmed low
testosterone receiving effective testosterone treatment.
This may also explain the robust increase in lean mass
of 3.4 kg, compared to 1.6–2.7 kg in previous meta-
analyses [18, 19]. Testosterone treatment did not prevent
the loss of lean mass during the 10-week VLED suggest-
ing that testosterone treatment lacks anabolic actions
during acute severe caloric restriction. However,
10 weeks of treatment may be too short to manifest
changes in body composition, since testosterone-
mediated changes in lean mass are evident only after
several months [18, 19].
Testosterone treatment significantly reduced the
metabolically important visceral fat even in the con-
text of a weight loss program. Previous RCTs of tes-
tosterone therapy, while not incorporating a weight
loss program, did not find a consistent reduction in
visceral fat [14, 15, 20, 21], most likely because of
small trial size [15], use of oral testosterone therapy
[20], or less precise methodology to quantify visceral
adipose tissue [20]. None of these RCTs specifically
targeted obese men.
Interestingly, the differences in body composition were
evident despite the modest increase in endogenous tes-
tosterone levels in placebo-treated men similar to previ-
ous weight loss studies [22]. Indeed, this increase by
2.9 nmol/L in TT and 30.3 pmol/L in free testosterone
with 10.8 % weight loss was very similar to that reported
in a meta-analysis of low caloric diet studies [23]. Thus,
the endogenous rise in testosterone subsequent to diet
appears not to be sufficient to prevent diet-associated
loss of lean mass.
What are the potential mechanisms by which testos-
terone treatment leads to these changes in body com-
position? Testosterone, via androgen receptor signalling,
inhibits stem cell differentiation into adipocytes and fa-
vours myogenesis [6]. Androgen receptor signalling in
mature adipocytes promotes lipolysis [24] and activates
anabolic pathways in myocytes [25]. The effect on fat
mass may also be mediated by aromatisation to estradiol
[26]. Testosterone may also have motivational effects
leading to increased physical activity; in RCTs, testoster-
one treatment reduces fatigue and inertia [27], and an-
drogen-deficient mice have decreased voluntary
activity [28]. We advised subjects to perform at least





Difference between groupsa P valueb
Fat mass, kg
Week 0–10 –7.9 (–9.7 to –6.1)* –7.5 (–9.4 to –5.7)* –0.4 (–3.0 to 2.2) 0.78
Week 0–56 –9.4 (–11.3 to –7.5)* –6.5 (–8.5 to –4.5)* –2.9 (–5.7 to –0.2) 0.04
Fat mass, %
Week 0–10 –3.8 (–4.9 to –2.6)* –3.0 (–4.3 to –1.8)* –0.7 (–2.4 to 1.0) 0.40
Week 0–56 –5.7 (–6.9 to –4.5)* –2.9 (–4.3 to –1.6)* –2.8 (–4.6 to –1.0) 0.003
Lean mass, kg
Week 0–10 –3.9 (–5.3 to –2.6)* –4.8 (–6.2 to –3.5)* 0.9 (–1.0 to 2.8) 0.36
Week 0–56 –0.6 (–2.0 to 0.8) –4.0 (–5.5 to –2.5)* 3.4 (1.3 to 5.5) 0.002
VAT area, mm2
Week 0–10 –7688 (–9333 to –6044)* –6590 (–8267 to –4912)* –1099 (–3448 to 1251) 0.36
Week 0–56 –7223 (–8921 to –5526)* –4545 (–6383 to –2708)* –2678 (–5180 to –176) 0.04
Body weight, kg
Week 0–10 –12.0 (–14.5 to –9.5)* –13.5 (–16.0 to –11.0)* 1.5 (–2.0 to 5.1) 0.40
Week 0–56 –11.4 (–13.9 to –8.8)* –10.9 (–13.6 to –8.1)* –0.5 (–4.3 to 3.3) 0.80
Data are mean (95 % CI)
aDifference between groups (mean adjusted difference) refers to the change over time across groups (linear mixed effects model)
bP value refers to the overall significance of the change between groups during follow-up
*P < 0.05 within group
VAT visceral abdominal tissue
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30-minutes of moderate-intensity exercise each day.
Subjects completed exercise questionnaires and accel-
erometer testing, with feedback given, to reinforce
and encourage participation in exercise. Both men re-
ceiving testosterone and placebo increased their activ-
ity during the weight loss phase. However, only men
receiving testosterone (P = 0.03) but not placebo (P = 0.28)
maintained increased activity levels at study end, suggest-
ing that increased physical activity may have contributed
to the observed changes in body composition in
testosterone-treated men.
Supervised exercise programs may promote loss of fat
mass and attenuate loss of muscle mass during weight
loss, but are less effective than caloric restriction to
achieve weight loss. Exercise interventions are not well
characterised for obese men with low testosterone and
require high volume interventions, which may be
difficult to achieve even in a dedicated RCT [29]. Only
few studies have randomised obese men receiving caloric
restriction to exercise programs. The effects of testoster-
one reported here compare favourably; systematic re-
views have estimated that the addition of exercise to
energy restriction increases the loss of fat mass by 1.6 kg
[30] but does not fully protect against the loss of lean
mass that occurs with diet, reducing this by 50 % [2]. In
the Look Ahead study, men, despite assignment to an
intensive lifestyle intervention, lost 2.5 kg of lean mass
in the first study year [31].
Metabolic parameters, evidenced by decreases in
HOMA-IR, HbA1c, triglycerides, and increases in HDL
levels improved in both groups. Testosterone treatment
had no added benefit, despite resulting in changes in body
composition expected to be metabolically favourable. Our
study was not designed to examine this outcome, and





Between group P valuea
BMI, kg/m2 –3.7* (–4.7 to –2.7) –3.6* (–4.8 to –2.3) –0.1 (–1.7 to 1.4) 0.85
Waist circumference, cm –11* (–14 to –8) –8* (–12 to –5) –3 (–7 to 2) 0.21
SBP, mmHg –1 (–6 to 3) –1 (–6 to 3) 0 (–6 to 6) 0.94
DBP, mmHg 0 (–3 to 3) –1 (–4 to 2) 1 (–3 to 5) 0.62
Handgrip, kg 1.7 (–0.5 to 3.8) –1.9 (–4.3 to 0.5) 3.6 (0.4 to 6.7) 0.03
ALM/height2, kg/m2 0.12 (–0.02 to 0.26) –0.33* (–0.50 to –0.15) 0.45 (0.22 to 0.67) <0.001
Step count per day 931* (116 to 1746) 606 (–186 to 1399) 325 (–794 to 1443) 0.56
Activity, %/day 1.5* (0.1 to 2.9) 0.7 (–0.6 to 2.1) 0.76 (–1.2 to 2.7) 0.43
Physical function test, sec –3.1* (–4.8 to –1.5) –2.7* (–4.1 to –1.3) –0.4 (–2.6 to 1.7) 0.67
TT, nmol/L, ECLIA 7.4* (5.7 to 9.1) 1.8* (0.4 to 3.1) 5.5 (3.4 to 7.7) <0.001
cFT, pmol/L, ECLIA 49* (37 to 60) 4 (–3 to 10) 46 (32 to 59) <0.001
SHBG, nmol/L 4* (2 to 6) 7* (3 to 10) –3 (–6.4 to 1.1) 0.16
LH, IU/L –4.0* (–4.7 to –3.4) 0.2 (–0.5 to 1.0) –4.3 (–5.2 to –3.3) <0.001
Fasting glucose, mmol/L –0.5* (–0.8 to –0.25) –0.3* (–0.5 to 0.0) –0.3 (–0.6 to 0.1) 0.19
HOMA-IR –0.8* (–1.1 to –0.5) –0.6* (–0.9 to –0.2) –0.2 (–0.7 to 0.3) 0.38
HbA1c, % –0.5* (–0.6 to –0.3) –0.3* (–0.5 to –0.2) –0.1 (–0.3 to 0.1) 0.19
Cholesterol, mmol/L –0.18 (–0.4 to 0.0) 0.0 (–0.2 to 0.2) –0.19 (–0.5 to 0.1) 0.23
LDL-C, mmol/L –0.1 (–0.3 to 0.1) –0.1 (–0.3 to 0.2) 0.0 (–0.3 to 0.3) 0.88
HDL-C, mmol/L 0.1* (0.1 to 0.2) 0.1* (0.0 to 0.2) 0.0 (–0.1 to 0.1) 0.66
Triglycerides, mmol/L –0.6* (–0.9 to –0.4) –0.4* (–0.6 to –0.1) –0.3 (–0.6 to 0.1) 0.17
Haematocrit 0.04* (0.03 to 0.05) –0.005* (–0.009 to –0.001) 0.04 (0.03 to 0.05) <0.001
Haemoglobin, g/L 14* (11 to 17) –2* (–3 to 0) 15 (12 to 19) <0.001
PSA, μg/L 0.3* (0.2 to 0.5) 0.1* (0.0 to 0.3) 0.2 (0.0 to 0.4) 0.10
Shown are within- and between-group differences between baseline and study end
The data are mean (95 % CI).
aP value refers to difference between groups at study end
*P < 0.05 versus baseline within group
BMI body mass index, DBP diastolic blood pressure, SBP systolic blood pressure, ALM appendicular lean mass, VAT visceral abdominal tissue, SHBG sex hormone
binding globulin, TT testosterone, cFT calculated free testosterone, ECLIA electrochemiluminescence immunoassay, LCMS liquid chromatography-tandem mass
spectroscopy, LH luteinising hormone, HbA1c glycated haemoglobin, LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol, PSA
Prostate-specific antigen
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men enrolled were relatively healthy, with a low propor-
tion of men being diabetic or dyslipidaemic at baseline.
Consistent with previous studies, we observed a sig-
nificant increase in haematocrit in testosterone-treated
men. Overall, serious adverse events were few and not
statistically different between groups, although this study
was not powered to assess safety. Ten percent of the
participants assigned to testosterone treatment had an
increase of above 1 μg/L in PSA during the study, simi-
lar to the 6 % among men allocated to testosterone in
the recent testosterone trials [32]. However, the signifi-
cance of this biochemical increase is uncertain, and al-
though definitive long-term studies are lacking, the
current evidence does not suggest that testosterone
treatment leads to clinically meaningful adverse prostate
outcomes.
Limitations include the enrolment of relatively healthy
men motivated to lose weight subjected to a profession-
ally administered diet and frequent monitoring. Despite
preservation of lean mass, testosterone treatment, with
the exception of increased grip strength, did not affect
muscular performance. Previous studies have suggested
that testosterone treatment improves physical perform-
ance primarily in frail, mobility-limited men [33, 34].
Although we did not include a supervised exercise pro-
gram, exercise recommendations were reinforced at
every visit, and men assigned to testosterone but not
placebo, had increased activity levels. We selected partic-
ipants based on a TT of less than 12 nmol/L to include
men with modestly reduced levels typical of the majority
of obese men [3]. This allowed us to capture the large
population in whom testosterone treatment (be it re-
placement or pharmacological) is more controversial
than in men with more profound reductions in testoster-
one, or indeed with organic hypogonadism. While TT
may reflect adaptation to obesity-associated lowering
of SHBG, it is important to emphasize that 97 % of
our study population had a baseline free testosterone
(calculated from LCMS/MS total testosterone) of less than
243 pmol/L, the lower limit reported for healthy young
men [4], and 89 % a level of less than 220 pmol/L, the cut-
off for late onset hypogonadism [35]. While we did not
find an added effect of testosterone treatment on diet-
induced loss of body weight in this 56-week study, it is
possible that the duration of our study was insufficient,
given that a recent meta-analysis of observational studies
has suggested that testosterone treatment may be associ-
ated with time-dependent weight loss that may only be
evident after 2 years of treatment [36]. Finally, our study
was not designed to examine cardio-metabolic outcomes.
Conclusions
Among obese men with a low to low-normal testosterone
typical for the majority of obese men, testosterone treat-
ment augmented diet-induced loss of total fat and visceral
fat mass, and preserved lean mass so that, in contrast to
placebo-treated men who lost both lean and fat mass,
diet-induced weight loss during testosterone treatment
was almost exclusively due to the loss of body fat.
Additional file
Additional file 1: Table S1. Change in main outcomes compared to
baseline within and between groups analysed by intention to treat.
Figure S1. Circulating testosterone and luteinising hormone levels in
placebo- and testosterone-treated men. Shown are (median, IQR)
circulating total testosterone (TT) (A), calculated free testosterone (B)
and luteinising hormone (C) levels at the indicated time points during the
trial in men receiving placebo or testosterone, respectively. Circulating
testosterone levels at 26 and 56 weeks represent trough levels, which
were in the therapeutic trough range (10–15 nmol/L for TT) in testosterone-
treated men. By contrast, testosterone levels at week 10 were obtained
4 weeks after injection of the study drug and represent a 4-week
post injection peak, which is higher than the recommended trough
range. Figure S2. Body weights in placebo and testosterone treated men.
Shown are mean (95 % CI) body weights in kilogram in placebo- (grey line)
and testosterone-treated men from baseline to 56 weeks. (PDF 321 kb)
Abbreviations
ALM: Appendicular lean mass; BMI: Body mass index; cFT: Calculated free
testosterone; CI: Confidence interval; CT: Computed tomography;
CV: Coefficient of variability; DXA: Dual-energy X-ray absorptiometry; LCMS/
MS: Liquid chromatography-tandem mass spectroscopy; LME: Linear mixed
models; MAD: Mean adjusted between group difference; PSA: Prostate-
specific antigen; RCT: Randomized, double-blind, placebo-controlled trial;
SHBG: Sex hormone binding globulin; TT: Total testosterone; VLED: Very low
energy diet






Any adverse event 10 8




Rise in prostate-specific antigen
by > 1.0 μg/L
5* 0
Prostatitis 1 0






aA total of three men were withdrawn from the study: one man receiving
testosterone experienced angina requiring coronary artery stent insertion, one
man receiving testosterone had a rise in prostate-specific antigen above the
pre-determined safety level (>5.5 μg/L) at week 26, one man receiving placebo
experienced ventricular fibrillation and was resuscitated
bThe rise in haemoglobin above the pre-determined safety level (>180 g/L)
occurred at study end
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